display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - triple negativebreast cancer HER 2 negative
es-BC - TNBC - NA - all populationmBC - HER 2 negative
durvalumab based treatment
durvalumab alone GeparNuevo Saphir02 Breast-Immuno

Study type:

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons